Sunvozertinib
Dizal Pharmaceuticals
['sunvozertinib']
 impressive 60% orr (ci: 50-70) with sunvozertinib for egfr exon20 ins mutations (3rd most common egfr mutation) a number of studies in this space but look forward to ph3 data #asco2023 
Thoracic Medical Oncologist @BartsHospital, PhD in genomic medicine @Imperialcollege, Representative @ACPUK & @BTOGorg, @FMLM_UK clinical Fellow ‘18